Windfire Capital Corp. (“Windfire”) is publicly traded company, and the company is led by an experienced management team comprised of public market professionals and skilled operational people from the Medical Marijuana industry.
Windfire has executed definitive agreement with Rosebud Productions Inc., (“Rosebud”) located in British Columbia. Rosebud has submitted an application to Health Canada to become a LP of Medical Marijuana under the new MMPR .
2015 Aphria Medical Marijuana Investor PresentationAphriaMMJ
Aphria Inc (TSXV:APH)
Aphria is a licensed producer of Medical Marijuana under the laws of Marijuana for Medical Purposes Regulations.
Aphria is publicly traded on the TSX Venture Exchange under the symbol APH.V
Aurora investor presentation - April 2018hughcarter
The document provides an overview of Aurora Cannabis Inc., a company focused on the production and distribution of medical cannabis. Key points:
- Aurora has over 280,000 kg per year of funded production capacity across several facilities.
- The company pursues growth through innovation, execution, expansion internationally and through acquisitions. It has acquired 8 companies and made 7 strategic investments.
- Aurora is well positioned for international growth, with existing sales or operations in Germany, Denmark, Italy, Australia, Cayman Islands, and South Africa. It aims to capitalize on medical cannabis markets in Europe and globally.
Aurora investor presentation acquisition of canni-med therapeuticsMarc Lakmaaker
- Aurora has acquired CanniMed Therapeutics to form a medical cannabis centre of excellence and gain CanniMed's drug delivery technologies and strong brands.
- The acquisition adds 19,000 kg per year of funded production capacity and expands Aurora's international footprint.
- The combination of Aurora and CanniMed enhances Aurora's medical offerings with CanniMed's four balanced ratio cannabis strains.
Corporate presentation january 17, 2017 - finalcorpaveda2015
This document is a corporate presentation for Aveda Transportation and Energy Services Inc. regarding a preliminary short form prospectus offering of securities. It provides an overview of Aveda's history and operations, but cautions investors that the information is not comprehensive and that the securities have risks. It directs readers to the prospectus for full disclosure and includes standard disclaimers about forward-looking statements and non-IFRS measures.
This corporate investor presentation provides an overview of Sorrento Therapeutics' immuno-oncology and non-opioid pain management programs. Key points include: Sorrento has an industry-leading CD38 CAR-T program for the treatment of multiple myeloma, with IND filing planned for 1Q18 and first patient enrollment in 1H18. Sorrento is also developing next-generation CAR-T technologies including non-viral gene modification and allogeneic "off-the-shelf" CAR-T cells derived from cord blood. Additionally, Sorrento is exploring oncolytic virus therapies in combination with CAR-T cells to potentially treat solid tumors.
Aurora investor presentation - january 2018AuroraCannabis
This document provides an overview of Aurora Cannabis Inc., a leading cannabis company. It discusses Aurora's positioning in the global cannabis market, which is projected to be worth $159 billion worldwide. The summary highlights Aurora's focus on agility, innovation, execution, and expansion to capitalize on opportunities both domestically and internationally. It also summarizes Aurora's rapid growth and progress in cultivation facilities, strategic partnerships, revenue growth, capitalization, domestic and global expansion, and achieving scale, reach and differentiation in the cannabis industry.
Aurora investor presentation - january 2018AuroraCannabis
This document provides an overview and presentation for Aurora Cannabis Inc. It discusses Aurora's positioning in the global cannabis market, strategies for growth through innovation, execution, expansion, and strategic partnerships. Key points include Aurora's rapid growth and progression as one of the fastest growing LP's in Canada, plans for major cultivation facilities including Aurora Sky and Nordic projects, and international expansion through acquisitions in Germany and investments in other markets like Australia. Financial metrics and assumptions are also presented regarding operating capacity, sales prices, and cash costs.
2015 Aphria Medical Marijuana Investor PresentationAphriaMMJ
Aphria Inc (TSXV:APH)
Aphria is a licensed producer of Medical Marijuana under the laws of Marijuana for Medical Purposes Regulations.
Aphria is publicly traded on the TSX Venture Exchange under the symbol APH.V
Aurora investor presentation - April 2018hughcarter
The document provides an overview of Aurora Cannabis Inc., a company focused on the production and distribution of medical cannabis. Key points:
- Aurora has over 280,000 kg per year of funded production capacity across several facilities.
- The company pursues growth through innovation, execution, expansion internationally and through acquisitions. It has acquired 8 companies and made 7 strategic investments.
- Aurora is well positioned for international growth, with existing sales or operations in Germany, Denmark, Italy, Australia, Cayman Islands, and South Africa. It aims to capitalize on medical cannabis markets in Europe and globally.
Aurora investor presentation acquisition of canni-med therapeuticsMarc Lakmaaker
- Aurora has acquired CanniMed Therapeutics to form a medical cannabis centre of excellence and gain CanniMed's drug delivery technologies and strong brands.
- The acquisition adds 19,000 kg per year of funded production capacity and expands Aurora's international footprint.
- The combination of Aurora and CanniMed enhances Aurora's medical offerings with CanniMed's four balanced ratio cannabis strains.
Corporate presentation january 17, 2017 - finalcorpaveda2015
This document is a corporate presentation for Aveda Transportation and Energy Services Inc. regarding a preliminary short form prospectus offering of securities. It provides an overview of Aveda's history and operations, but cautions investors that the information is not comprehensive and that the securities have risks. It directs readers to the prospectus for full disclosure and includes standard disclaimers about forward-looking statements and non-IFRS measures.
This corporate investor presentation provides an overview of Sorrento Therapeutics' immuno-oncology and non-opioid pain management programs. Key points include: Sorrento has an industry-leading CD38 CAR-T program for the treatment of multiple myeloma, with IND filing planned for 1Q18 and first patient enrollment in 1H18. Sorrento is also developing next-generation CAR-T technologies including non-viral gene modification and allogeneic "off-the-shelf" CAR-T cells derived from cord blood. Additionally, Sorrento is exploring oncolytic virus therapies in combination with CAR-T cells to potentially treat solid tumors.
Aurora investor presentation - january 2018AuroraCannabis
This document provides an overview of Aurora Cannabis Inc., a leading cannabis company. It discusses Aurora's positioning in the global cannabis market, which is projected to be worth $159 billion worldwide. The summary highlights Aurora's focus on agility, innovation, execution, and expansion to capitalize on opportunities both domestically and internationally. It also summarizes Aurora's rapid growth and progress in cultivation facilities, strategic partnerships, revenue growth, capitalization, domestic and global expansion, and achieving scale, reach and differentiation in the cannabis industry.
Aurora investor presentation - january 2018AuroraCannabis
This document provides an overview and presentation for Aurora Cannabis Inc. It discusses Aurora's positioning in the global cannabis market, strategies for growth through innovation, execution, expansion, and strategic partnerships. Key points include Aurora's rapid growth and progression as one of the fastest growing LP's in Canada, plans for major cultivation facilities including Aurora Sky and Nordic projects, and international expansion through acquisitions in Germany and investments in other markets like Australia. Financial metrics and assumptions are also presented regarding operating capacity, sales prices, and cash costs.
American International Holdings (AMIH) is an investor, developer and asset manager of diversified, synergistic health and wellness businesses. Today, the AMIH portfolio encompasses telemedicine and other virtual health platforms, affordable subscriber-based primary care and concierge medicine plans, preventative care solutions and wellness related assets such as mental & behavioral health services, as well as its own proprietary life coaching platform. AMIH markets its various services through direct-to-consumer and business-to-business distribution channels. AMIH’s focus is on bringing to market technologies and solutions that advance the quality of life for the global community.
New health plan identifier & certifucation requirements for self insured plansPatti Goldfarb, CSA
The ACA and HIPAA require self-insured health plans to obtain and use a 10-digit health plan identifier (HPID) for certain electronic transactions by set deadlines. Large plans must get an HPID by November 2014 and certify compliance by December 2015, while small plans have until November 2015 and an additional 365 days to certify. Failure to comply may result in penalties per covered individual. Employers should identify applicable plans, obtain HPID numbers according to size, and update third party agreements to require HPID use by November 2016.
This document discusses Diplomat Pharmacy's business and financial performance. It summarizes Diplomat's growth strategies, including expanding into high-margin businesses like specialty infusion, growing key therapeutic areas in oncology and immunology, and pursuing strategic partnerships and acquisitions. The document also outlines Diplomat's competitive advantages in the specialty pharmacy market and its multiple avenues for continued strong growth and financial performance.
This presentation discusses Teranga Gold Corporation's plans for future growth and opportunities. It contains forward-looking statements regarding anticipated production levels, costs, cash flows, and the completion of construction projects. It also provides cautionary notes about the risks and uncertainties inherent in forward-looking mining projections. Additionally, the presentation provides Teranga's capital structure details and share price performance compared to gold price and market indices.
Can-Fite is a clinical stage drug development company developing oral small molecule drugs for inflammatory and cancer indications. Their lead drugs, Piclidenoson and Namodenoson, have shown efficacy and safety in Phase II/III studies for psoriasis, liver cancer, and NASH. Piclidenoson has commenced a Phase II study in COVID-19 patients. Can-Fite has outlicensed their drugs in select territories, receiving $20M to date with potential for $130M more in milestones and royalties. They are well positioned financially to advance their clinical programs targeting multi-billion dollar markets.
Valeant reported strong financial results for the third quarter of 2014, with total revenue growing 33% year-over-year to $2.1 billion and cash EPS growing 48% to $2.11. Several key business segments saw double-digit organic growth, including the recently acquired Bausch + Lomb business and emerging markets. Valeant also provided an update on its proposed acquisition of Allergan, noting potential regulatory hurdles and uncertainties remaining around a potential combination.
This presentation discusses MedReleaf's forward-looking statements and non-IFRS measures, provides an overview of the company's operations and facilities, highlights its financial and operational performance to date, and outlines its growth strategies and milestones for the next 18 months. Key points include that MedReleaf has achieved over 80% market share in the Canadian medical cannabis market, has expanded production capacity through a new facility, and aims to leverage its expertise internationally and participate in the potential Canadian recreational cannabis market.
Longwood Capital Advisors seeks funding from private investors to invest in public biotech and pharmaceutical companies. It focuses on small-cap companies with drugs in late-stage clinical trials or pending FDA approval. By leveraging the partners' medical and scientific expertise, LCA analyzes clinical data and FDA processes to evaluate investment opportunities. Since 2012, LCA has generated an average annual return of 28.8% while mitigating risk through position size limits and automatic stop losses.
APA Group is offering to acquire all remaining securities of Ethane Pipeline Income Fund (EPX) that it does not already own. The unconditional offer price is $1.88 per EPX security plus retention of the declared 3.25 cent distribution for the March 2016 quarter, totaling $122 million. The acquisition provides APA with ownership of a long-term ethane pipeline asset that is strategically important to its core business and offers certainty of value to EPX securityholders. EPX's independent directors unanimously recommend acceptance of the offer, subject to no superior proposal and a positive independent expert's opinion.
Medicine Man Technologies provides cannabis consulting services and products to cannabis growers nationwide and internationally. Their services include consulting, cultivation optimization through their Cultivation Max program, and cannabis nutrients sold under the Success Nutrients brand. Medicine Man has acquired companies to expand their product and service offerings and pursue a strategy of building a "cannabis brand warehouse". They have experienced rapid revenue growth in recent years and expect new acquisitions and cross-selling opportunities to further drive sustainable revenue growth.
Tcelna is a precision immunotherapy under development by Opexa Therapeutics for the treatment of multiple sclerosis (MS). Opexa is currently conducting a Phase IIb clinical trial of Tcelna in patients with secondary progressive MS (SPMS). Previous clinical trials of Tcelna in both relapsing-remitting and SPMS patients showed promising results, including a 37% reduction in annualized relapse rate in a Phase IIb RRMS trial. Opexa has an option agreement with Merck Serono for the development and commercialization of Tcelna in MS that could provide over $220 million in payments if milestones are achieved.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
- Stocks came under renewed pressure this week as volatility remained elevated. Year-to-date gains have been erased and major stock indexes have moved towards or through their October lows.
- Sentiment indicators show rising investor pessimism, with bulls falling and bears rising, reflecting the most pessimism since early 2016. This emerging pessimism could allow for meaningful lows to be made in the stock market.
- While latent investor optimism has prevented panic selling so far, evidence that pessimism is increasing may lead to further volatility but also provides an environment where stock prices can find a bottom.
The IDFC Sterling Value Fund follows a value investment strategy, predominantly investing in mid and small cap stocks. It takes a benchmark-agnostic approach and evaluates relative value using metrics like Enterprise Value/Sales ratio and Price/Book value. The fund can also be described as a mix of leaders and challengers in non-Nifty and Nifty50 sectors as well as emerging business opportunities.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
Newt is a cloud-based Software as a Service (SaaS) platform enabling enterprises to offer digital financial products and services. Digital financial technologies and infrastructure are reshaping payments, commerce, and access to financial services, creating a growing market opportunity for digital financial service disruptors like Newt.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
2016 Beneplan HR Workshop - Marijuana in the Workplace and Travel Insurance ...Beneplan
This document discusses various topics related to marijuana, including:
- Marijuana is already widely used in Canada despite its legal status.
- Employers have a duty to accommodate medical marijuana use by employees.
- Recreational marijuana use in the workplace could be restricted by policies limiting non-medical use.
- Travel insurance may cover costs associated with cancelled trips due to certain covered risks like medical emergencies, but pre-existing conditions are often excluded.
This person is now physically and psychologically dependent on the substance. Their life revolves around obtaining and using the substance and they have lost control over their use. Their health and relationships are seriously impacted.
Conference Board of Canada Presentation: Medical marijuana in the workplaceRudner Law
This document summarizes key points from a presentation on accommodating medical marijuana in the workplace. It discusses the duty to accommodate under human rights law, including establishing discrimination, bona fide occupational requirements, and undue hardship. It reviews case law related to medical marijuana and outlines best practices for employers, such as having clear policies and processes for responding to accommodation requests and managing suspected abuse. Employers are advised to avoid stereotyping, consider human rights issues, and document all aspects of assessing and determining accommodations.
American International Holdings (AMIH) is an investor, developer and asset manager of diversified, synergistic health and wellness businesses. Today, the AMIH portfolio encompasses telemedicine and other virtual health platforms, affordable subscriber-based primary care and concierge medicine plans, preventative care solutions and wellness related assets such as mental & behavioral health services, as well as its own proprietary life coaching platform. AMIH markets its various services through direct-to-consumer and business-to-business distribution channels. AMIH’s focus is on bringing to market technologies and solutions that advance the quality of life for the global community.
New health plan identifier & certifucation requirements for self insured plansPatti Goldfarb, CSA
The ACA and HIPAA require self-insured health plans to obtain and use a 10-digit health plan identifier (HPID) for certain electronic transactions by set deadlines. Large plans must get an HPID by November 2014 and certify compliance by December 2015, while small plans have until November 2015 and an additional 365 days to certify. Failure to comply may result in penalties per covered individual. Employers should identify applicable plans, obtain HPID numbers according to size, and update third party agreements to require HPID use by November 2016.
This document discusses Diplomat Pharmacy's business and financial performance. It summarizes Diplomat's growth strategies, including expanding into high-margin businesses like specialty infusion, growing key therapeutic areas in oncology and immunology, and pursuing strategic partnerships and acquisitions. The document also outlines Diplomat's competitive advantages in the specialty pharmacy market and its multiple avenues for continued strong growth and financial performance.
This presentation discusses Teranga Gold Corporation's plans for future growth and opportunities. It contains forward-looking statements regarding anticipated production levels, costs, cash flows, and the completion of construction projects. It also provides cautionary notes about the risks and uncertainties inherent in forward-looking mining projections. Additionally, the presentation provides Teranga's capital structure details and share price performance compared to gold price and market indices.
Can-Fite is a clinical stage drug development company developing oral small molecule drugs for inflammatory and cancer indications. Their lead drugs, Piclidenoson and Namodenoson, have shown efficacy and safety in Phase II/III studies for psoriasis, liver cancer, and NASH. Piclidenoson has commenced a Phase II study in COVID-19 patients. Can-Fite has outlicensed their drugs in select territories, receiving $20M to date with potential for $130M more in milestones and royalties. They are well positioned financially to advance their clinical programs targeting multi-billion dollar markets.
Valeant reported strong financial results for the third quarter of 2014, with total revenue growing 33% year-over-year to $2.1 billion and cash EPS growing 48% to $2.11. Several key business segments saw double-digit organic growth, including the recently acquired Bausch + Lomb business and emerging markets. Valeant also provided an update on its proposed acquisition of Allergan, noting potential regulatory hurdles and uncertainties remaining around a potential combination.
This presentation discusses MedReleaf's forward-looking statements and non-IFRS measures, provides an overview of the company's operations and facilities, highlights its financial and operational performance to date, and outlines its growth strategies and milestones for the next 18 months. Key points include that MedReleaf has achieved over 80% market share in the Canadian medical cannabis market, has expanded production capacity through a new facility, and aims to leverage its expertise internationally and participate in the potential Canadian recreational cannabis market.
Longwood Capital Advisors seeks funding from private investors to invest in public biotech and pharmaceutical companies. It focuses on small-cap companies with drugs in late-stage clinical trials or pending FDA approval. By leveraging the partners' medical and scientific expertise, LCA analyzes clinical data and FDA processes to evaluate investment opportunities. Since 2012, LCA has generated an average annual return of 28.8% while mitigating risk through position size limits and automatic stop losses.
APA Group is offering to acquire all remaining securities of Ethane Pipeline Income Fund (EPX) that it does not already own. The unconditional offer price is $1.88 per EPX security plus retention of the declared 3.25 cent distribution for the March 2016 quarter, totaling $122 million. The acquisition provides APA with ownership of a long-term ethane pipeline asset that is strategically important to its core business and offers certainty of value to EPX securityholders. EPX's independent directors unanimously recommend acceptance of the offer, subject to no superior proposal and a positive independent expert's opinion.
Medicine Man Technologies provides cannabis consulting services and products to cannabis growers nationwide and internationally. Their services include consulting, cultivation optimization through their Cultivation Max program, and cannabis nutrients sold under the Success Nutrients brand. Medicine Man has acquired companies to expand their product and service offerings and pursue a strategy of building a "cannabis brand warehouse". They have experienced rapid revenue growth in recent years and expect new acquisitions and cross-selling opportunities to further drive sustainable revenue growth.
Tcelna is a precision immunotherapy under development by Opexa Therapeutics for the treatment of multiple sclerosis (MS). Opexa is currently conducting a Phase IIb clinical trial of Tcelna in patients with secondary progressive MS (SPMS). Previous clinical trials of Tcelna in both relapsing-remitting and SPMS patients showed promising results, including a 37% reduction in annualized relapse rate in a Phase IIb RRMS trial. Opexa has an option agreement with Merck Serono for the development and commercialization of Tcelna in MS that could provide over $220 million in payments if milestones are achieved.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
- Stocks came under renewed pressure this week as volatility remained elevated. Year-to-date gains have been erased and major stock indexes have moved towards or through their October lows.
- Sentiment indicators show rising investor pessimism, with bulls falling and bears rising, reflecting the most pessimism since early 2016. This emerging pessimism could allow for meaningful lows to be made in the stock market.
- While latent investor optimism has prevented panic selling so far, evidence that pessimism is increasing may lead to further volatility but also provides an environment where stock prices can find a bottom.
The IDFC Sterling Value Fund follows a value investment strategy, predominantly investing in mid and small cap stocks. It takes a benchmark-agnostic approach and evaluates relative value using metrics like Enterprise Value/Sales ratio and Price/Book value. The fund can also be described as a mix of leaders and challengers in non-Nifty and Nifty50 sectors as well as emerging business opportunities.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
Newt is a cloud-based Software as a Service (SaaS) platform enabling enterprises to offer digital financial products and services. Digital financial technologies and infrastructure are reshaping payments, commerce, and access to financial services, creating a growing market opportunity for digital financial service disruptors like Newt.
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. From public safety to pop culture, Draganfly has shaped not just the UAV industry, but the way people around the world work and live. Breaking ground with international firsts, Draganfly has a legacy of leading the professional drone industry, including releasing the first commercialized quadrotor UAV in 1999 and releasing the first multirotor UAV with an integrated camera system in 2001. In 2013, Draganflyer was credited as the world’s first small unmanned aerial system (sUAS) to save a person’s life, and in 2016, Draganfly became the first company to have multiple UAV systems deemed Transport Canada Compliant.
2016 Beneplan HR Workshop - Marijuana in the Workplace and Travel Insurance ...Beneplan
This document discusses various topics related to marijuana, including:
- Marijuana is already widely used in Canada despite its legal status.
- Employers have a duty to accommodate medical marijuana use by employees.
- Recreational marijuana use in the workplace could be restricted by policies limiting non-medical use.
- Travel insurance may cover costs associated with cancelled trips due to certain covered risks like medical emergencies, but pre-existing conditions are often excluded.
This person is now physically and psychologically dependent on the substance. Their life revolves around obtaining and using the substance and they have lost control over their use. Their health and relationships are seriously impacted.
Conference Board of Canada Presentation: Medical marijuana in the workplaceRudner Law
This document summarizes key points from a presentation on accommodating medical marijuana in the workplace. It discusses the duty to accommodate under human rights law, including establishing discrimination, bona fide occupational requirements, and undue hardship. It reviews case law related to medical marijuana and outlines best practices for employers, such as having clear policies and processes for responding to accommodation requests and managing suspected abuse. Employers are advised to avoid stereotyping, consider human rights issues, and document all aspects of assessing and determining accommodations.
The document outlines the contents of an HR policy manual for a company. It includes sections on the company overview, employment policies, employment status and records, employee benefits, payroll, workplace guidelines, and e-policies. The policy aims to establish principles for managing employees and provide guidance to HR on topics such as hiring, compensation, time off, conduct, and technology usage.
This survey by the Society for Human Resource Management examined policies related to marijuana use in the workplace in states that have legalized medical and/or recreational marijuana use. The key findings were:
1) The vast majority (94%) of organizations surveyed had a formal substance use policy, with policies specifically addressing marijuana use more common where it was legalized for both medical and recreational use.
2) Most organizations (73-82%) had a zero-tolerance policy prohibiting marijuana use while working.
3) Common disciplinary actions for first violations included termination (41-50%), mandatory drug counseling (16-21%), and written warnings (14-19%).
4) Around half of organizations conducted pre-employment
To change the perception, alter stereotypes and to create awareness around marijuana production and usage to non-traditional patients, current users and investors of this fast growing industry.
This will be achieved through the implementation of professional, structured and robust production methods with a laser focus on enhanced research and development including an unequivocal commitment to quality and adherence to all industry regulations and laws.
This document describes a company called Red Earth Cannabis that provides cannabis infused product development, manufacturing, and packaging services. It aims to establish best-in-class benchmarks for the cannabis supply chain and leverage existing manufacturing methods. The company sees opportunities in value-added cannabis products as the market shifts towards distribution agreements and branding. It intends to partner with cannabis brands to provide private label manufacturing, packaging, and distribution services globally.
The document is an investor presentation for Flower One Holdings Inc. that provides an overview of the company, its flagship cannabis cultivation and production facility in Nevada, financial performance, leadership team, and growth strategy. Key points include Flower One operating the largest greenhouse facility in Nevada with potential annual production capacity of over 100,000 pounds, generating increasing quarterly revenues, restructuring to reduce debt and costs, and an experienced new leadership team to execute on strategic expansion plans.
Tetra Bio-Pharma is a Canadian company developing cannabinoid-derived pharmaceutical drugs. Its CEO Guy Chamberland is considering next steps for building the Tetra brand and overcoming stigma around medical marijuana applications. Canada recently legalized recreational marijuana use, creating medical and recreational consumer markets as well as a pharmaceutical market for approved drugs. Tetra's strategy is to position itself in the pharmaceutical market through rigorous clinical trials and acquiring Drug Identification Numbers from Health Canada to gain physician trust and insurance reimbursement. It must accelerate brand-building plans before its first drug PPP001 is approved in 2019.
This document summarizes a presentation given by Cardinal Health executives on December 16, 2016. The presentation provided an overview of Cardinal Health's offerings and support for independent pharmacies and their customers. Several Cardinal Health executives spoke on topics such as retail solutions and strategies, the pharmaceutical segment, and the medical segment. The presentation included a question and answer session with the executives.
Flower One Holdings Inc. provides an investor presentation on their flagship cannabis cultivation and production facility in Nevada. The presentation highlights Flower One's 400,000 square foot greenhouse facility, the largest in Nevada, with a potential annual production capacity of over 100,000 pounds. It also outlines Flower One's 55,000 square foot production facility and their partnerships with over a dozen leading cannabis brands. The presentation discusses Flower One's leadership team and board of directors as well as the company's financial performance, showing increasing quarterly revenues.
Flower One Holdings Inc. provides an investor presentation on their flagship cannabis cultivation and production facility in Nevada. The presentation highlights Flower One's 400,000 square foot greenhouse facility, the largest in Nevada, with a potential annual production capacity of over 100,000 pounds. It also outlines Flower One's 55,000 square foot production facility and their partnerships with over a dozen leading cannabis brands. The presentation discusses Flower One's leadership team and board of directors as well as the company's financial performance, with quarterly revenues increasing from $1 million in Q1 2019 to over $11 million in Q3 2020.
MMJ BioPharma Labs, Inc. is one of the first United States DEA approved Analytical Lab specializing in Marijuana, Cannabinoids, and Marijuana based extracts, and concentrated products.
MMJ BioPharma Labs will offer a comprehensive menu of services ranging from analytical research and development (R&D) and quality control (QC) testing, marijuana extraction under controlled environment, cannabinoids purification, cannabis product formulation, as well as quality analysis .
Marijuana: The #1 Profit Opportunity for Greenhouse Growers in the Next DecadeGGS Structures Inc.
The document discusses the potential opportunities for greenhouse growers in the cannabis industry over the next decade. It notes that the legal cannabis market in the US and Canada is projected to be worth $44 billion by 2020. It provides an overview of the medical cannabis programs in Canada and regulations for licensed producers. The document also discusses factors for greenhouse growers to consider such as ventilation, lighting, irrigation and computer controls if pursuing cannabis cultivation. It emphasizes doing research and evaluating what skills align with long-term goals before deciding to enter the emerging industry.
Investor presentation for Flower One Holdings, updated for Q2 2020. The Company's common shares are traded on the Canadian Securities Exchange under the Company's symbol "FONE", in the United States on the OTCQX Best Market under the symbol "FLOOF" and on the Frankfurt Stock Exchange under the symbol "F11". For more information, visit: https://flowerone.com.
The investor presentation is for Flower One Holdings, a cannabis company based in Nevada. Flower One operates the largest cannabis greenhouse in Nevada, as well as an indoor cultivation facility and a post-harvest production facility. The company has partnerships with several leading cannabis brands to provide cultivation, extraction, manufacturing, distribution, and marketing services. Flower One believes its scale, low production costs, and partnerships with top brands give it a competitive advantage in the Nevada cannabis market.
Tetra Bio-Pharma is a biopharmaceutical company focused on developing cannabis-based prescription drugs and consumer products. They are developing several prescription drug products including PPP001 for smoked marijuana and PPP002 for cancer pain. They also plan to commercialize cannabis-based consumer products in partnership with McGill University. Tetra takes a pharmaceutical approach to cannabis research to generate the evidence needed for regulatory approval and physician prescription of their products.
LOVE - Cannara Biotech - Corporate PresentationMomentumPR
Headquartered in Montreal, Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000-square-foot facility. Leveraging Quebec's low electricity costs, Cannara's facility will produce high-grade hydroponically grown indoor cannabis and cannabis derivative products for the Canadian and international markets. Working with partners from various industries, Cannara will generate licensing revenues, rental revenues and revenue streams from joint venture arrangements leveraging this highly valuable property.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
This document provides an agenda for a Cardinal Health, Inc. Dublin Day event on June 1, 2017. The agenda includes opening remarks by company leadership, presentations on the Specialty Solutions and Pharmaceutical segments, and Q&A sessions. It also discusses Cardinal Health's role in the growing specialty pharmaceutical industry, including its end-to-end solutions across the product lifecycle and extensive provider distribution footprint. Finally, it outlines how Cardinal Health is well-positioned to help manufacturers, providers and patients in the biosimilars market through regulatory, marketing, distribution, analytics and patient support services.
Zomedica is revolutionizing veterinary health care with a focus on addressing unmet needs through its expanding product portfolio of innovative diagnostics and medical devices designed to improve pet health as well as productivity and practice profitability for veterinarians. With modest cash burn and a strong balance sheet, including $158.5 million cash, cash equivalents, and available-for-sale securities as of September 30, 2022, Zomedica is well-positioned to fund both organic growth and acquisitions. The Company’s current product portfolio includes: TRUFORMA® - in-clinic diagnostics with canine and feline assays; TRUVIEW® - innovative digital imaging technologies; VetGuardian® - wireless remote monitoring of vital signs; Assisi® tPEMF® - targeted pulsed electromagnetic field therapy; PulseVet® - global market leader in shock wave therapy in equine and small animal market.
Crop is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The company's portfolio of projects includes cultivation properties in California, Washington State, Nevada, Italy, Jamaica, and a joint venture on West Hollywood and San Bernardino dispensary applications. Crop has developed a portfolio of 15 cannabis brands and has U.S. and Italian distribution rights to a line of over 55 topical cannabis products from The Yield Growth Corp.
Medicine Man Technologies provides an investor presentation summarizing their business. They offer cannabis consulting services, cultivation techniques, and nutrient products across multiple states. The presentation highlights their recent financial results, new clients, federal policy developments, and growth strategy through acquisitions. Medicine Man Technologies aims to be a leading cannabis brand and consulting company in the United States and internationally.
CanniMed Therapeutics Inc. is a Canadian pharmaceutical company and leader in the medical cannabis industry with 15 years of experience cultivating cannabis. It has GMP-compliant production facilities and a clinical research program. CanniMed raised $69 million in its IPO to fund expansion and clinical trials to validate medical cannabis for pain relief. It focuses on pharmaceutical-grade products including cannabis oils to address the needs of the growing medical cannabis market and aging population seeking pain treatment alternatives.
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Sathish Vemula
News Uptoday
New Guidance
Audit Findings
- Diabetes Corporation of America
- Pine Pharmaceuticals
Warning Letters
- Warning letter: American Family Pharmacy
- Warning letter: Dr. Reddy's Laboratories Limited
- Warning letter: Sandoz Private Limited
Article of the Month
- Data Integrity Checklist related to Electronic Records and Electronic Signatures.
Regulations of the Month
- Sec. 211.46 Ventilation, air filtration, air heating and cooling
- Sec. 211.48 Plumbing
Similar to Windfire Capital - Medical Marijuana Firm (20)
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Co-Chairs, Val J. Lowe, MD, and Cyrus A. Raji, MD, PhD, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/AAPA activity titled “Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/3PvVY25. CME/AAPA credit will be available until June 28, 2025.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
1. Medical
Marijuana
Corporate Presentation
November 2014
This presentation does not constitute an offer to sell or solicitation of
an offer to buy any of the securities described herein. The sole
purpose of this presentation, in paper or electronic form, is strictly for
information.
3. About Windfire Capital Corp.
• Windfire Capital Corp. (“Windfire”) is publicly traded company on the TSX
Venture Exchange, TSX.V ("WIF"), and the company is led by an experienced
management team comprised of public market professionals and skilled
operational people from the Medical Marijuana industry.
• Windfire has received conditional approval to list on Canadian Securities
Exchange (CSE) as a Life Science issuer and subsequently delist from the TSX.V.
• Windfire has executed definitive agreement with Rosebud Productions Inc.,
(“Rosebud”) located in Richmond, British Columbia. Rosebud has submitted an
application to Health Canada to become a LP of Medical Marijuana under the
new MMPR.
• Windfire sees this agreement with Rosebud as being the first step in becoming
a multi licensed producer. On that basis, Windfire continues to search for other
related opportunities in the Medical Marijuana industry and looks forward to
becoming a leading producer of the highest quality Medical Marijuana.
3www.windfirecapital.com
4. About Rosebud Productions Inc.
Rosebud, a private company incorporated under the laws of British
Columbia.
Rosebud has an application pending with Health Canada for the newly
implemented MMPR license. Once the application is approved Rosebud
expects to be producing Medical Marijuana by next spring.
The Rosebud team consists of seasoned industry personnel with
experience in all aspects of Medical Marijuana production including
cultivation, facility design and construction.
Incoming Windfire board member Gary Quo Vadis and partner Jesse
McConnell are the founders and controlling shareholders of Rosebud.
Gary Quo Vadis currently holds a licence under the MMAR regulations.
www.windfirecapital.com 4
5. The Opportunity
Government of Canada is both exiting the production business and
eliminating the practice of allowing nearly 30,000 home growers.
Marijuana* for Medical Purposes Regulations legislation from Health Canada has
defined a commercial supply chain.
The Canadian Association of Chiefs of Police has been working closely with
Health Canada to ensure these regulations address public safety considerations.
Medical marijuana grew from under 500 prescriptions in 2002 to more than
28,000 in 2012 and is expected to reach 40,000 in 2014.
A recent Health Canada survey indicates ~2.0% of Canadians believe they are
eligible to use medicinal marijuana, compared to 0.08% of the population
currently benefiting from use.
2.0% participation is consistent with other jurisdictions where access
requirements have been relaxed (i.e. Colorado).
5www.windfirecapital.com
6. In June 2013, the Government of Canada published the new Marijuana for
Medical Purposes Regulations (“MMPR”) replacing the existing marijuana
Medical Access Program (“MMAR”) that was introduced in 2001
In 2001, there were 500 authorized users of medicinal marijuana in
Canada, today there are 35,000+
MMPR Regulations
MMPR (2013)
Required specialist consultation and prescription including 20-page application form
Licensed commercial producers
Regulated quality control standards
Physical security regulations and enforcement
Detailed record keeping and audit from seed to end product
Ability to purchase directly from Health Canada
www.windfirecapital.com 6
7. Investment Highlights
Proven Management
Experienced operational
cultivation team
Application submitted to
Health Canada
Superior Growth Strategy
Strong growth predicted
industry wide.
www.windfirecapital.com 7
8. How the MMPR Process Works
Patients obtain a prescription from a medical doctor
for medicinal marijuana with a Health Canada
prescription number.
To purchase the medicinal marijuana, patients must
provide their original prescription to a commercial
producer.
Authorized patients then select a commercial
producer to fill and ship their prescription.
No advertising is permitted under new MMPR
regulations. Patients will select a vendor from
Health Canada’s website, medical practitioner
or brand awareness.
Prescription are shipped directly from the
producer’s facility to the patient using a bonded
courier.
www.windfirecapital.com 8
9. The Market
The present market is estimated at 37,000 patients.
According to Health Canada, the current licenses translate to about 3.5
million plants.
If each of those 3.5 million plants contributed an average of 56 grams that
equates to $1.4 billion at an average price of $7.15. This number does not
include the recreational user who buys on the black market.
Health Canada anticipates by 2024 there will be more than 450,000 people
using marijuana for medical reasons, creating billions in annual sales.
A majority of people in Canada believe marijuana should be readily available
for those who want to use it.
A recent Angus Reid Public Opinion poll has found:
– In the online survey of representative national samples, a majority of Canadians (57%) and
Americans (54%) support the legalization of marijuana.
– Most respondents in each Canadian region back the legalization of cannabis, including 64
per cent of Atlantic Canadians and 60 per cent of British Columbians.
www.windfirecapital.com 9
10. Review of Potential Market
The number of prescription users in
Canada is expected to grow tenfold
over the next ten years.
Health Canada has issued 23 licenses
to date.
Estimates indicate 37,000 patients
will use an average of 2 grams per
day equating to 27,010 kg and will
grow to 270,100 kg over the next ten
years.
Recently released Liberal Party of
Canada research indicates 3 million
users in Canada equating to a six
billion dollar market place.
www.windfirecapital.com 10
11. Financial Projections
11www.windfirecapital.com
2015 2016 2017 2018 2019
Revenue $2,939,650 $7,055,160 $10,317,150 $16,126,080 $26,210,328
Net Income $917,522 $3,653,911 $5,760,732 $9,734,278 $16,767,606
New Equity Investment $3,500,000 $1,500,000 $1,500,00
Cash From Operations $995,424 $3,848,406 $5,995,199 $10,077,907 $17,096,338
Total Assets $4,897,230 $10,160,618 $17,508,278 $27,441,095 $44,382,900
Total Equity $4,850,932 $10,004,843 $17,265,575 $26,999,852 $43,767,458
Earnings per Share (assume 45.5M) $0.02 $0.08 $0.13 $0.21 $0.37
Return on Equity 18.9% 36.5% 33.4% 36.1% 38.3%
Return on Revenue 31.2% 51.8% 55.8% 60.4% 64.0%
Financials Projections Summary – Year Ending December 31, 2015-2019
12. Revenue & Income Growth 5YR
www.windfirecapital.com 12
2015 2016 2017 2018 2019
Revenue $2,939,650 $7,055,160 $10,317,150 $16,126,080 $26,210,328
Net Income $917,522 $3,653,911 $5,760,732 $9,734,278 $16,767,606
Revenue & Income Growth
13. Review of Competition
Industry experts expect high margins as prices initially range from
$5-$20 per gram while production costs are expected to be $1-$2
per gram.
Operating expenses will include capital expenditures, production,
sales & marketing, and security.
Successful companies will be those that can demonstrate the
ability to manufacture, deliver, and scale quickly.
Producers will have to have experienced cultivation and
horticulture specialists, careful quality control and security
measures, and thorough record keeping procedures to satisfy
Health Canada
13www.windfirecapital.com
14. The Acquisition – Rosebud
Pursuant to the terms of the share exchange agreement signed July 15,
2014, the total purchase price, $5 million for Rosebud.
Windfire will make an advance payment of $250,000 dollars to
Rosebud on exchange approval.
A 2nd cash payment of $750,000 will be made to Rosebud on
conformation that Health Canada has issued a permit to build the
cultivation / production facility.
A 3rd cash payment of $1,000,000 dollars will be made to Rosebud on
Health Canada granting the MMPR license to operate.
A final payment of $3,000,000 dollars in shares will be paid in two
tranches over two years based on performance criteria.
www.windfirecapital.com 14
15. Technical Team
Cindy Chow, B.Sc. in Food, Nutrition, and Health – Quality Assurance / Safety Manager
Miss Chow has over 8 years’ experience in the food industry specializing in Quality
Assurance, Regulatory Affairs, HPLC, Research and Development and Internal Auditing
Solid understanding of GFSI recognized schemes with internal audit experience against
BRC and FSSC 22000 standards and ISO 9001:2008 standards
Extensive knowledge of CFIA/FDA regulations and labelling of various RTE products
Experienced in HACCP, GMP, GLP, and Pre-requisite Programs
Outstanding trouble-shooting, problem solving, and time management skills with the
ability to work effectively in a team based environment or independently
Dean Laidlow – Chief Technical Advisor
Mr. Laidlow has consulted both domestically and internationally in the Medical
Marijuana Industry for many years during which time he has developed a vast pool of
contacts.
Dean has supervised numerous medical marijuana facilities on a day to day basis
resulting in an intimate understanding of all operational aspects of commercial medical
marijuana growing facilities. Additionally, he has designed and been instrumental in the
construction phase of numerous growing facilities.
www.windfirecapital.com 15
16. Technical Team Cont’d.
Victor Lam – Head Grower
Mr. Lam as head grower has managed all activities related to growing with
Rosebud.
Mr. Lam has knowledge of large scale commercial plant cultivation including
nutrient requirements, mediums, light requirements, temperature control, and air
flow.
Has experience managing a large-scale warehouse with 100 thousand watt grow
lights.
Manages plant scheduling and organization to precisely project all garden needs
on a daily, weekly, and monthly basis to keep garden green and expenses low.
Responsible for Cataloging and analyzing each individual strain from clone to
flower to harvesting.
Working knowledge in container systems with soil and hydro as well as
understanding temperature and humidity manipulation.
Develop and/or maintain grow warehouse protocols and nutrient regiment.
Oversee work force of 10 employees.
www.windfirecapital.com 16
17. Facility Build Out
The cost of the facility is
estimated to be $500,000. This
cost includes, upgrading the fire
suppression system, adding
4,200 sq. ft. of mezzanine area,
purchasing panel wall system,
upgrading the electrical systems
and installing a state of the art
security system including a
vault.
www.windfirecapital.com
Projects ($000) Costs
Vault $50
Mezzanine build out $125
Wall paneling system $90
Fire suppression system $40
Security system $30
Inventory management & POS system $15
Lights, Co2 system, ventilation $150
Total Capital Expenditure $500
17
18. Management & Board
Clive Massey – President & Chief Executive Officer and Director
Mr. Massey was previously the President and Chief Executive Officer of Universal
Uranium Inc. from 2005 to 2007. From 2005 to 2007, Mr. Massey worked for
several successful public companies including Lumina Copper Corp., which was
purchased by Teck Cominco Ltd. in 2008. Mr. Massey has held management or
investor relations positions with Inca Pacific, Greystar Resources, Marafill Mines,
Everett Resources Ltd. and The North Air Group of Companies.
Brian Morrison, BComm – Chief Financial Officer and Director
Mr. Morrison received a bachelor of commerce degree from the University of
Northern British Columbia in 2004, and completed the Canadian securities course
in 2006. From January, 2005, to May, 2008, Mr. Morrison was an account manager
with Computershare Investor Services Inc., an international full-service financial
services, corporate trust and stock transfer company, and since June, 2008, he has
been a self-employed consultant working in the area of public company
administration. Mr. Morrison currently serves and has previously served as a
director or as chief financial officer of various publicly traded issuers.
18www.windfirecapital.com
19. Management & Board Cont’d.
Robert C. Harrison – Director
Mr. Harrison has spent 35 years as an executive in branding, marketing and
General Management and after having attained the position of Senior Vice
President and General Manager of William Neilson Ltd. Mr. Harrison went on to
build several other very successful brands and was responsible for acquiring the
licenses and launching both Haagen Dazs and Ben & Jerry's Ice Cream in Canada.
Mr. Harrison has consulted for many Fortune 500 companies including Heinz,
Nabisco, Nestle and Slim Fast. He has an extensive corporate background in
product branding, licensing, manufacturing and the food processing industry. Mr.
Harrison is currently President of Global Garden Group of Vancouver, B.C., which is
a dairy-free natural food beverage. He was also responsible for engaging and
securing the license in Canada for Cadbury and Weight Watchers and in raising in
excess of $30 million for plant construction and operational deployment. His
extensive back ground includes, numerous debt and equity financings, reverse
take overs and the creation of a business strategy that has resulted in business
growth in excess of 50% year over year.
19www.windfirecapital.com
20. Management & Board Cont’d.
Gary Quo Vadis, BBA – Director
Mr. Quo Vadis has a diverse business background that includes start-up businesses
and or buying existing businesses over the last 25 years. Gary is the founding partner
of Rosebud Productions, a Medical Marijuana Company applicant under MMPR and
he is also a partner in Whistler Medical Marijuana Corporation, one of only 13
licensed producers under Health Canada MMPR. Gary also holds a medical marijuana
license under the MMAR. Gary’s strengths are in business development and
identifying opportunities for business growth. Gary has a strong skill set in
developing business relationships whether both domestically and internationally.
Gary’s education includes a Bachelor of Business Administration from the University
of Regina with a major in marketing. Through Gary’s experience and education, he
has developed strong analytical skills.
Robert Hall, BEd – Director
Mr. Hall brings over 10 years’ experience in management in both public and private
companies to Windfire Capital Corp. He is active as a director and officer of multiple
Canadian reporting issuers. Mr. Hall is formally educated with a Bachelor of
Education from the University of British Columbia.
20www.windfirecapital.com
21. OFFERING SIZE: A maximum of $600,000
Financing – Terms
Each Unit consists of one Common Share (“Share”) and one-
half (1/2) transferable Warrant (“Warrant”).
Each Whole Warrant shall entitle the holder to purchase an
additional Common Share for $0.25, and is exercisable for a
period of 24 months from the distribution date.
www.windfirecapital.com
OFFERING: A maximum of 4,000,000 units ( “Unit”), will be offered
through a combined Brokered and non Brokered private placement.
OFFERING PRICE: $0.15 per Unit
21
22. Share Structure
Share Structure
Issued & Outstanding 25,535,355
Warrants 6,006,000
Options 2,250,000
Fully Diluted 33,791,355
As of July 20, 2014
www.windfirecapital.com 22
23. Contact Information
www.windfirecapital.com
For further information, please contact:
Clive Massey – President & CEO
(604) 669-2191 O
(604) 644-6794 C
clive@windfirecapital.com
Brian Morrison – CFO & Director
(604) 669-2191 O
(604) 312-6910 C
brian@windfirecapital.com
23
24. Disclaimer
Ontario
The following statutory rights of action for damages or rescission will only apply to a purchase of securities of the Company in the event that this presentation is deemed to be an offering
memorandum pursuant to securities law applicable in the Province of Ontario. These remedies, or notice with respect thereto, must be exercised, or delivered, as the case may be, by the
purchaser within the time limits prescribed by the applicable provisions of Ontario securities law. Purchasers should refer to such applicable securities legislation for the complete text of
these rights or consult with a legal adviser. Where used in this section, "misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is
required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made.
Ontario securities law provides that when an offering memorandum is delivered to an investor to whom securities are distributed in reliance upon the "accredited investor" prospectus
exemption provided in Section 2.3 of National Instrument 45-106 (the "Accredited Investor Exemption"), the right of action described below is applicable, unless the prospective
purchaser is: (a) an association governed by the Cooperative Credit Associations Act (Canada) or a central cooperative credit society for which an order has been made under Section
473(1) of that Act; (b) a bank, loan corporation, trust company, trust corporation, insurance company, treasury branch, credit union, caisse populaire, financial services corporation, or
league that, in each case, is authorized by an enactment of Canada or a jurisdiction of Canada to carry on business in Canada or a jurisdiction in Canada; (c) a Schedule III bank, meaning
an authorized foreign bank named in Schedule III of the Bank Act (Canada); (d) the Business Development Bank of Canada incorporated under the Business Development Bank of Canada
Act (Canada); or (e) a subsidiary of any person referred to in paragraphs (a), (b), (c) or (d), if the person owns all of the voting securities of the subsidiary, except the voting securities
required by law to be owned by the directors of the subsidiary.
Where an offering memorandum that contains a misrepresentation is delivered in connection with a trade made in reliance on the Accredited Investor Exemption or certain other
exemptions available under Ontario securities law, a purchaser who purchases a security offered by the offering memorandum during the period of distribution will have, without regard
to whether the purchaser relied on the misrepresentation, a statutory right of action for damages against the issuer and a selling security holder on whose behalf the distribution was
made or, while still the owner of securities against the issuer or selling security holder on whose behalf the distribution was made for rescission. If the purchaser elects to exercise the
right of rescission, the purchaser will have no right of action for damages. The right of action will be exercisable by the purchaser only if the purchaser commences the action, in the case
of any action for rescission, not more than 180 days after the date of the transaction that gave rise to the cause of action and in the case of any action, other than an action for rescission,
before the earlier of: (i) 180 days after the plaintiff first had knowledge of the facts giving rise to the cause of action, or (ii) three years after the date of the transaction that gave rise to
the cause of action.
A defendant will not be liable for a misrepresentation if it proves that the purchaser purchased the securities with knowledge of the misrepresentation. In an action for damages, the
defendant shall not be liable for all or any portion of the damages that the defendant proves do not represent the depreciation in value of the securities as a result of the
misrepresentation relied upon. In no case shall the amount recoverable for the misrepresentation that exceeds the price at which the securities were offered.
United States
This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any such offer to sell or solicitation of an
offer to buy the securities described herein or during the presentation will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any
such offering will be made in the United States in reliance upon an exemption from registration under the U.S. Securities Act of 1933, as amended (the "US Securities Act"), for an offer
and sale of securities that does not involve a public offering, and the offer and sale of the securities will be conditioned on the receipt of representations, warranties and agreements of
prospective purchasers to establish that exemption.
Any securities described in this document have not been, and will not be, registered under the US Securities Act and may not be offered or sold in the United States except in transactions
exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.
www.windfirecapital.com 24